Clinical Trials in Boston

Showing 5921-5940 of 17,836 trials

Pharmacokinetics and Pharmacogenomics of Ribociclib in Race-based Cohorts

NCT04657679

The aim is to determine the pharmacological and biochemical association between ribociclib exposure and CYP3A variants in African American/Blacks and Non-Hispanic White patients. The investigators hypothesize that patients treated with ribociclib who are CYP3A5 poor metabolizers may be exposed to higher levels of ribociclib than CYP3A5 intermediate or normal metabolizers. The findings could allow clinicians to tailor treatments to maintain therapeutic doses while limiting toxicities.

Breast Cancer

Georgetown University21 participantsStarted May 2021

Washington D.C., District of Columbia, United States • Washington D.C., District of Columbia, United States • Boston, Massachusetts, United States

RECRUITINGPhase 1< 1 mile

A Study of ZN-c3 in Patients With Ovarian Cancer

NCT04516447

This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of ZN-c3 in combination with other drugs.

Solid TumorEpithelial Ovarian CancerFallopian Tube Cancer+1 more

K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc140 participantsStarted Oct 2020

Aurora, Colorado, United States • Boston, Massachusetts, United States • St Louis, Missouri, United States +21 more locations

Pharmacokinetics and Pharmacogenomics of Ribociclib in Race-based Cohorts

A Study of ZN-c3 in Patients With Ovarian Cancer

Find Trials by Condition in Boston

Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery

A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer

Working Memory Training for People Aging with HIV

Digital Health Interventions for Obsessive Compulsive Disorder (OCD)

Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction

A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF)

Pegtibatinase As an Enzyme Therapy for Patients with Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency (COMPOSE)

Effect of a Targeted Notification and Clinical Support Pathway on Individuals With Left Ventricular Hypertrophy

Glyburide Advantage in Malignant Edema and Stroke Pilot

Analysis of Both Sex and Device Specific Factors on Outcomes in Patients with Non-Ischemic Cardiomyopathy

A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)

Real-World Evaluation of Eko Algorithms in a Point of Care Setting

Positive Airway Pressure, Sleep Apnea, and the Placenta (PAP-SAP)

FPA150 in Patients With Advanced Solid Tumors

Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants

Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

Adjunctive Fosfomycin for Treatment of Staphylococcus Aureus Bacteraemia